Patients with erectile dysfunctions and multiple comorbidities: A look into drug-related problems
Nov 10, 2021
Huri HZ and co-authors conducted a study in a tertiary medical center in Kuala Lumpur, Malaysia, wherein a total of 200 erectile dysfunction (ED) patients with 499 cases who had received pharmacological treatments for their ED participated in this study. Types, causes and factors associated with drug-related problems (DRPs) in ED patients with multiple comorbidities were evaluated.
Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder: Randomized, placebo-controlled, double-blind, parallel group clinical study
Nov 10, 2021
Bray R and co-authors evaluated the effect of tolterodine extended release (TER) versus placebo on bladder wall thickness (BWT) using transvaginal ultrasound in women with overactive bladder (OAB). They recruited 79 women with symptoms of OAB with a mean age of 47 years who had a BWT of at least 5 mm and a post-micturition volume of less than 50 mL at screening.
Traditional and Emerging Surgical Therapies for Lower Urinary Tract Symptoms in Men: A comparative review
Nov 10, 2021
Lower urinary tract symptoms (LUTS) are one of the most common health problems in men and pose a significant economic challenge in healthcare. Transurethral resection of the prostate (TURP) remains the gold standard surgical treatment for medically refractive LUTS secondary to benign prostatic hyperplasia (BPH).
Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment
Nov 10, 2021
Kim and co-authors conducted a prospective, multi-centre clinical study to identify incidence and risk factors of recurrence after discontinuation of successful antimuscarinic therapy in patients with overactive bladder (OAB). Patients who had antimuscarinic agents for > 12 weeks and showed successful response were included.
Androgen deprivation therapy for prostate cancer: an update on lifestyle guidelines
Nov 10, 2021
Men treated with androgen deprivation therapy (ADT) for prostate cancer (PC) are susceptible to multiple treatment-induced adverse effects such as deterioration in bone health and altered body composition (decreased lean tissue mass and increased fat mass). These alterations may partially explain the marked increased risk in osteoporosis, falls, fracture and cardiometabolic risk that has been observed in such patient population.
Drug-food interactions of drugs treating overactive bladder syndrome
Nov 10, 2021
Overactive bladder (OAB) syndrome is a condition where one or more of the symptoms such as pollakiuria, urgent need to urinate, nocturia and urinary incontinence have been observed. Its prevalence ranges between 9-43 % in women and 7 and 27 % in men. Pasko and co-authors aimed to assess a potential impact of food and fruit juice on the pharmacokinetic and therapeutic effects of drugs used in treating OAB syndrome.
Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis
Nov 10, 2021
Hussain and co-workers conducted a clinical study to estimate the risk of developing skeletal-related events (SREs) based on site of metastasis at diagnosis and identify other predictors of developing SREs among metastatic prostate cancer patients.
Management of urinary tract infections in the era of antimicrobial resistance: An update
Nov 10, 2021
A growing concern is urinary tract infections (UTIs) that are caused by antibiotic-resistant Gram-negative bacteria due to limited therapeutic options.